Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

ABSTRACT: The gene expression profiling between Control and Luteolin in 22Rv1

ORGANISM(S): Homo sapiens

PROVIDER: GSE126856 | GEO | 2022/02/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

Project description:The miRNA expression profiling between Control and Luteolin in 22Rv1

2021-08-30 | GSE120181 | GEO

Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

Project description:Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

| PRJNA491894 | ENA

Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

Project description:Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment

| PRJNA523525 | ENA

22RV1 prostate cancer cell line transfected with SPINK1 siRNA vs control siRNA

Project description:ETS gene fusions have been characterized in a majority of prostate cancers, however key molecular alterations in ETS negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier-expression exclusively in a subset of ETS rearrangement negative cancers (~10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier-expression can be detected non-invasively in urine and observed that SPINK1 outlier-expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier-expression model, and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement negative prostate cancers. Keywords: Genetic Modification 22RV1 cells were infected with non-targeting siRNA or siRNA against SPINK1. For reported hybridizations, the reference channel is 22RV1 cells infected with non-targeting siRNA. Duplicate hybridizations were performed with duplicate dye flips, for a total of four arrays. Over and under-expressed signatures were generated by filtering to include only features with significant differential expression (PValueLogRatio < 0.01) in all hybridizations and Cy5/Cy3 ratios > or < 1 in all hybridizations.

2008-06-10 | E-GEOD-11132 | biostudies-arrayexpress

22RV1 prostate cancer cell line transfected with SPINK1 siRNA vs control siRNA

2008-06-10 | GSE11132 | GEO

Gene Expression of Prostate Cancer Cells; 22Rv1, DU-145 and LNCaP: 5-Aza-2'-deoxycytidine (DAC) Treatment vs. Control

Project description:Epigenetic silencing mediated by CpG methylation is a common feature of many cancers. Characterizing aberrant DNA methylation changes associated with tumor progression may identify potential prognostic markers for prostate cancer (PCa). We treated three PCa cell lines, 22Rv1, DU-145 and LNCap with the demethylating agent 5-aza 2’–deoxycitidine (DAC) and examined gene expression changes using a custom microarray (GPL16604). These data were integrated with gene methylation status (GEO Pending) in PCa cell lines and further combined with patient tumor data to identify potential novel biomarkers for PCa patients. In order to identify genes that are methylated in PCa, we employed a genome-wide gene expression profiling approach and compared cells treated with 5-aza 2’–deoxycitidine (DAC) to untreated cells. 22Rv1, DU-145 and LNCaP PCa cell lines were incubated in culture medium with 2 μg/mL DAC for 4 days with medium change every 2 days. Total RNA was extracted and gene expression was analyzed using a custom microarray (GPL16604).

2014-11-13 | GSE63196 | GEO

Human prostate carcinoma cell line 22Rv1 overexpressing ESE1

Project description:Activation of the inflammatory circuits occurs frequently in cancer cells. However the molecular details linking inflammation to transformation and progression are still unknown. In this study we report for the first time, that activation of the ETS factor ESE1 is a key event connecting inflammatory signaling with prostate cancer progression. We report that ESE1 is induced upon IL-1 beta stimulation by NFKB and mediates key transcriptional changes involving cell adhesion, migration and invasion. ESE1 activation in turn induces NFKB transcriptional activation and intranuclear translocation and mediates the transforming phenotypes linked to the activation of IL-1B. Transcriptional signatures and immunohistochemistry revealed that this ESE1-NFKB regulatory circuit also operates in prostate tumors, particularly in those with significant elevation of ESE1. Thus, ESE1 promotes an inflammatory feed forward loop positively leading to prostate cancer progression. Pharmacological NFKB inhibition reverted the transformed status of ESE1 cell lines providing a rationale for context-dependent therapeutic strategies in ESE1 activated tumors. These studies find a previously unrecognized link between ETS and activation of the NFKB pathway and open new avenues for prostate cancer treatment. Gene expression analysis of a control cell line (22Rv1-pcDNA3.1) and a testing cell lines (22Rv1-ESE1), with two replicates, with dye swap, performed for each sample.

2013-06-20 | E-GEOD-39668 | biostudies-arrayexpress

transcriptome analysis for luteolin or siVRK1 treated ovarian cancer cells

Project description:To investigate the function of Luteolin and siVRK1 on ovarian cancer, we use A2780 and ES2 cell lines treated with siCtrl, siVRK1, DMSO and luteolin to do the experiment. We then performed gene expression profiling analysis using data obtained from RNA-seq .

2022-09-07 | GSE212598 | GEO

Analysis of gene expression in EIF3F knockdown 22Rv1 prostate cancer cells

Project description:Total RNA was obtained from 22Rv1 cells with or without EIF3F interference to perform a High-throughput sequencing

2022-11-15 | GSE140526 | GEO

Effects of CDK8/19 Mediator Kinase inhibition on gene expression in castration-resistant prostate cancer cell line 22Rv1 and its derivatives grown in vitro.

Project description:RNA-Seq analysis was carried out to investigate the effects of selective CDK8/19 inhibitor SNX631 on gene expression in different 22RV1 derivatives grown in cell culture, under androgen-supplemented and androgen-deprived conditions. The 22Rv1 derivatives were generated as following: Parental 22Rv1 (Rv1-WT) were transduced with a lentivirus expressing luciferase, yielding the derivative Rv1-Luc. 22Rv1 cells with a double knockout of CDK8 and CDK19 (Rv1-dKO) were made via CRISPR/Cas9. Rv1-dKO cells were further transduced with lentiviruses to generate Rv1-dKO re-expression derivatives that express wild-type CDK8 or CDK19 (Rv1-dKO-CDK8 or Rv1-dKO-CDK19) and kinase-inactive D173A mutants (Rv1-dKO-CDK8M or Rv1-dKO-CDK19M).

2024-03-31 | GSE240369 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data